Sign In

Eric Halioua

President & Chief Executive Officer at PDC*line Pharma

Eric Halioua is a prominent figure in the biotechnology and life sciences industry, currently serving as a Board Member at essenscia, specifically for bio.be/essenscia, the Belgian federation of companies active in life sciences and biotechnologies.13

Professional Background

Eric Halioua is a serial entrepreneur with extensive experience in strategic, technological, and managerial aspects of the biotech industry. His career highlights include:

Current Positions:

  • President and CEO of PDC*line Pharma, a biotechnology company12
  • Board Member at essenscia (bio.be) since January 20211
  • Founder and Managing Partner of CarKath sprl, offering strategic advisory and corporate finance services for the Life Sciences industry1

Past Roles:

  • Co-founder and CEO of Digital Orthopaedics (2016-2019)1
  • CEO of Promethera Biosciences (2009-2015)1
  • Board Director at European Biopharmaceutical Enterprises (2013-2015)1
  • Co-founder and CEO of MYOSIX (1999-2002), which was later acquired by Genzyme1

Achievements and Expertise

Eric Halioua has a proven track record in:

  • Bringing drug candidates from research to clinical trials (up to phase IIb)1
  • Fundraising, having raised over €160 million from VCs and strategic partners across Europe, USA, Japan, and Korea1
  • Deal-making and successful exits, including sales and initial public offerings of biotechnology companies1

Education

Halioua holds:

  • Two master's degrees in pharmacology and Molecular Biology
  • An MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair2

Eric Halioua's LinkedIn username is indeed "halioua", as mentioned in the query.1

Highlights

Jun 10 · linkedin

I'm excited to be speaking at the 6th Allogeneic Cell Therapies Summit - June 11th, 2024 in Boston! Agenda of the conference is available here ! https://ter.li/ztuzcc.

Apr 8 · linkedin

I am delighted to announce the interim clinical results from last cohort of patients in phase I/II trial with PDClung01 cancer vaccine presented yesterday at the American Association for Cancer Research (AACR) annual meeting. This data revealed that the high dose PDClung01 combined with pembrolizumab shows an immunological activity in a majority of patients and a promising antitumor response in stage IV Non-Small Cell Lung Cancer (NSCLC) with a mild safety profile. Combination of high dose PDC*lung01 with pembrolizumab in 19 evaluable patients resulted in objective response rate of 63.2% and median progression-free survival of 10.9 months!

PDClung01 is PDCline Pharma's off-the shelf therapeutic cancer vaccine candidate for Non-Small Cell Lung Cancer (NSCLC). The preliminary data on the last cohort of patients was presented today through both an oral presentation and a poster at the American Association for Cancer Research (AACR) Annual Meeting 2024.

The oral presentation is available here: https://lnkd.in/emSp6B4B The poster presentation is available here: https://lnkd.in/eaakuebC

Related Questions

What are Eric Halioua's main achievements at PDC*line Pharma?
How has Eric Halioua contributed to the biotechnology industry?
What companies has Eric Halioua co-founded?
What is the role of Essenscia in the Belgian biotechnology sector?
How did Eric Halioua's career start at Arthur D. Little?
Eric Halioua
Eric Halioua, photo 1
Eric Halioua, photo 2
Add to my network

Location

Brussels Metropolitan Area